[ad_1]
JHVEPhoto/iStock Editorial through Getty Images
- AbbVie’s Humira (adalimumab) can be taken off the formulary lists of many Cigna (NYSE:CI) well being care plans in 2025 in favor of cheaper biosimilar model.
- Members subsequent 12 months can get Simlandi from Teva (TEVA) and Alvotech (ALVO), Cyltezo from Boehringer Ingelheim, or an unbranded model of Hyrimoz from Novartis (NVS) division Sandoz.
- Despite the introduction of many Humira biosimilars, AbbVie nonetheless controls many of the marketplace for adalimumab thanks to offers made with pharmacy profit managers, in accordance to Reuters.
- In January, CVS Health mentioned that its Caremark PBM would remove Humira from its business formularies on April 1.
[ad_2]
Source: Seekingalpha